Axitinib
Axitinib (AG013736; trade name Inlyta) is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models and has shown partial responses in clinical trials with renal cell carcinoma (RCC) and several other tumour types. It was approved for RCC by the U.S. Food and Drug Administration after showing a modest increase in progression-free survival, though there have been reports of fatal adverse effects.
primaryTopic
Axitinib
Axitinib (AG013736; trade name Inlyta) is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models and has shown partial responses in clinical trials with renal cell carcinoma (RCC) and several other tumour types. It was approved for RCC by the U.S. Food and Drug Administration after showing a modest increase in progression-free survival, though there have been reports of fatal adverse effects.
has abstract
Axitinib (AG013736; trade name ...... orts of fatal adverse effects.
@en
L'axitinib (AG013736 ; Inlyta) ...... cliniques de carcinome rénal.
@fr
アキシチニブ(Axitinib、商品名:インライタ、開発コー ...... た。無増悪生存期間が若干延長したが致死的な副作用も発現した。
@ja
ATC prefix
ATC suffix
Bioavailability
CAS number
319460-85-0
ChEBI
FDA UNII code
C9LVQ0YUXG
IUPAC name
N-Methyl-2-3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
@en
PubChem
thumbnail
Wikipage page ID
14,705,695
Wikipage revision ID
723,195,763
ChEMBL
ChemSpiderID
elimination half-life
excretion
Faeces , urine
IUPHAR ligand
legal CA
legal US
licence EU
licence US
MedlinePlus
metabolism
molecular weight
3.86469e+2
protein bound
routes of administration
smiles
O=Cc4ccccc4Sc1ccc2cnnc2\C=C\c3ncccc3
StdInChIKey
RITAVMQDGBJQJZ-FMIVXFBMSA-N
tradename
Verifiedfields
verifiedrevid
458,042,196
Watchedfields
hypernym
comment
Axitinib (AG013736; trade name ...... orts of fatal adverse effects.
@en
L'axitinib (AG013736 ; Inlyta) ...... cliniques de carcinome rénal.
@fr
アキシチニブ(Axitinib、商品名:インライタ、開発コー ...... た。無増悪生存期間が若干延長したが致死的な副作用も発現した。
@ja